| Affymax(R) Receives $30 Million Milestone Payments for Database Lock of Phase ... - MarketWatch (press release) |
|
|
MarketWatch (press release)... to develop and commercialize Hematide(TM)/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients. ... read more |